|  Help  |  About  |  Contact Us

Publication : Intraperitoneal injection of IFN-? restores microglial autophagy, promotes amyloid-? clearance and improves cognition in APP/PS1 mice.

First Author  He Z Year  2020
Journal  Cell Death Dis Volume  11
Issue  6 Pages  440
PubMed ID  32514180 Mgi Jnum  J:382721
Mgi Id  MGI:8308910 Doi  10.1038/s41419-020-2644-4
Citation  He Z, et al. (2020) Intraperitoneal injection of IFN-gamma restores microglial autophagy, promotes amyloid-beta clearance and improves cognition in APP/PS1 mice. Cell Death Dis 11(6):440
abstractText  Autophagy is a major self-degradative process that maintains cellular homeostasis and function in mammalian cells. Autophagic dysfunction occurs in the early pathogenesis of Alzheimer's disease (AD) and directly regulates amyloid-beta (Abeta) metabolism. Although it has been proven that the cytokine IFN-gamma enhances autophagy in macrophage cell lines, whether the signaling cascade is implicated in Abeta degradation in AD mouse models remains to be elucidated. Here, we found that 9 days of the intraperitoneal administration of IFN-gamma significantly increased the LC3II/I ratio and decreased the level of p62 in APP/PS1 mice, an AD mouse model. In vitro, IFN-gamma protected BV2 cells from Abeta toxicity by upregulating the expressions of Atg7 and Atg5 and the LC3II/I ratio, whereas these protective effects were ablated by interference with Atg5 expression. Moreover, IFN-gamma enhanced autophagic flux, probably through suppressing the AKT/mTOR pathway both in vivo and in vitro. Importantly, using intravital two-photon microscopy and fluorescence staining, we found that microglia interacted with exogenous IFN-gamma and Abeta, and surrounded Abeta in APP/PS1;CX3CR1-GFP(+/-) mice. In addition, IFN-gamma treatment decreased the Abeta plaque load in the cortex and hippocampus and rescued cognitive deficits in APP/PS1 mice. Our data suggest a possible mechanism by which the peripheral injection of IFN-gamma restores microglial autophagy to induce the phagocytosis of cerebral Abeta, which represents a potential therapeutic approach for the use of exogenous IFN-gamma in AD.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

8 Authors

7 Bio Entities

0 Expression